References
1 Xu, W., Wen, X., Cong, X. & Jiang, W. COVID-19 mRNA vaccine, but not
a viral vector-based vaccine, promotes neutralizing anti-type I
interferon autoantibody production in a small group of healthy
individuals. J Med Virol 95 , e29137,
doi:10.1002/jmv.29137 (2023).
2 Alqatari, S. et al. Emergence of Post COVID-19 Vaccine
Autoimmune Diseases: A Single Center Study. Infect Drug Resist16 , 1263-1278, doi:10.2147/IDR.S394602 (2023).
3 Bastard, P. et al. Autoantibodies against type I IFNs in
patients with life-threatening COVID-19. Science 370 ,
doi:10.1126/science.abd4585 (2020).
4 Chang, R. et al. Risk of autoimmune diseases in patients with
COVID-19: A retrospective cohort study. EClinicalMedicine56 , 101783, doi:10.1016/j.eclinm.2022.101783 (2023).
5 Jaycox, J. R. et al. SARS-CoV-2 mRNA vaccines decouple
anti-viral immunity from humoral autoimmunity. Nat Commun14 , 1299, doi:10.1038/s41467-023-36686-8 (2023).
6 Lim, S. H. et al. Autoimmune and Autoinflammatory Connective
Tissue Disorders Following COVID-19. JAMA Netw Open 6 ,
e2336120, doi:10.1001/jamanetworkopen.2023.36120 (2023).
7 Peng, K. et al. Risk of autoimmune diseases following COVID-19
and the potential protective effect from vaccination: a population-based
cohort study. EClinicalMedicine 63 , 102154,
doi:10.1016/j.eclinm.2023.102154 (2023).
8 Philippot, Q. et al. Autoantibodies Neutralizing Type I IFNs in
the Bronchoalveolar Lavage of at Least 10% of Patients During
Life-Threatening COVID-19 Pneumonia. J Clin Immunol 43 ,
1093-1103, doi:10.1007/s10875-023-01512-9 (2023).
9 Vera-Lastra, O. et al. New Onset Autoimmune Diseases after the
Sputnik Vaccine. Biomedicines 11 ,
doi:10.3390/biomedicines11071898 (2023).
10 Psarras, A., Emery, P. & Vital, E. M. Type I interferon-mediated
autoimmune diseases: pathogenesis, diagnosis and targeted therapy.Rheumatology (Oxford) 56 , 1662-1675,
doi:10.1093/rheumatology/kew431 (2017).